Because the use of HRH1 antagonists was reported to reduce the risk of liver cancer development (21) and improve survival rates in patients with melanoma and breast cancer (8,9), an analysis of HRH1 expression levels and their prognostic significance was initiated in 39 different cancer types using the pan-cancer prognostic database, PRECOG. The gene discussed is HRH1; the disease is melanoma.